Schering CEO Hassan Will Add Personal Touch To Allergy Business Turnaround
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough CEO Fred Hassan will be directly involved in reviving the firm's declining allergy business following the Rx-to-OTC switch of Claritin in December 2002
You may also be interested in...
Claritin Generic Competition Grows As Impax Version Granted FDA Approval
FDA approval of a generic version of Schering-Plough's OTC Claritin Reditabs (loratadine 10 mg) is expected to make further inroads into the $175 mil. product
Claritin Generic Competition Grows As Impax Version Granted FDA Approval
FDA approval of a generic version of Schering-Plough's OTC Claritin Reditabs (loratadine 10 mg) is expected to make further inroads into the $175 mil. product
Claritin Generic Competition Grows As Impax Version Granted FDA Approval
FDA approval of a generic version of Schering-Plough's OTC Claritin Reditabs (loratadine 10 mg) is expected to make further inroads into the $175 mil. product